Sofgen Pharma Interim CEO files Form 3

Sofgen Pharma S.A. filed an initial ownership report for Interim CEO Melissa Andreia Silva Angelini.

Accepted by SEC EDGAR 03/18/2026 - 03:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Sofgen Pharma S.A. filed an initial ownership report for Interim CEO Melissa Andreia Silva Angelini. This Form 3 does not list any equity transactions or derivative holdings, and the summary data shows no reported purchases, sales, exercises, gifts, or restructurings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Sofgen Pharma S.A.'s Form 3 for Melissa Andreia Silva Angelini show?

The Form 3 for Sofgen Pharma S.A.'s Interim CEO Melissa Andreia Silva Angelini reports her initial insider status. It shows no recorded purchases, sales, option exercises, gifts, or restructurings and does not list any derivative positions in the summarized data provided.

Does the Sofgen Pharma (PROCF) Form 3 disclose any stock transactions by the Interim CEO?

No stock transactions are disclosed for the Interim CEO in this Form 3. The transaction summary shows zero buys, zero sells, zero exercises, and no gifts or restructurings, indicating no reportable trading activity in the issuer's securities in this filing snapshot.

Are there any derivative securities reported for Sofgen Pharma's Interim CEO on this Form 3?

No derivative securities are reported for the Interim CEO on this Form 3. The derivative summary is empty and the transaction summary lists zero derivative transactions, suggesting no options, warrants, or similar instruments are shown in this particular ownership report.

What role does Melissa Andreia Silva Angelini hold at Sofgen Pharma S.A. in this filing?

Melissa Andreia Silva Angelini is identified as an officer serving as Interim CEO of Sofgen Pharma S.A. in this Form 3. The filing records her status as a reporting person but does not show any related equity transactions or derivative positions in the summarized data.

Does the Sofgen Pharma Form 3 indicate if Melissa Andreia Silva Angelini is a 10% owner or director?

The Form 3 indicates that Melissa Andreia Silva Angelini is not a director and not a 10% owner. She is classified solely as an officer with the title Interim CEO, and the structured data flags those specific reporting person status fields accordingly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Silva Angelini Melissa Andreia

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR 33025

(City) (State) (Zip)

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)